NCT02259231
RTA 408 Capsules in Patients With Melanoma - REVEAL treatment 1 / 2 completed NCT02076646
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma treatment 1 / 2 unknown_status NCT02133222
Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy No drug interventions screening Not Available completed NCT05848739
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors treatment 1 recruiting NCT00730639
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies treatment 1 completed NCT05896839
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer treatment 1 / 2 recruiting NCT01032122
Rituximab in Metastatic Melanoma treatment 1 terminated NCT01055522
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma treatment 2 terminated NCT00747825
Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma diagnostic 1 terminated NCT00304525
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma treatment 1 / 2 completed NCT04941430
7T MRI Scan for the Early Detection of Melanoma Brain Metastases No drug interventions diagnostic Not Available recruiting NCT00670748
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer treatment 2 terminated NCT04616248
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors treatment 1 recruiting NCT02038348
Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study No drug interventions prevention 2 completed NCT01740557
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma treatment 1 / 2 completed NCT04703426
Sargramostim (GM-CSF) + PD-1 treatment 2 withdrawn NCT06424626
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma treatment 1 not_yet_recruiting NCT03415126
A Study of ASN007 in Patients With Advanced Solid Tumors No drug interventions treatment 1 completed NCT05510466
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis No drug interventions Not Available Not Available unknown_status NCT02065466
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases treatment 1 / 2 withdrawn NCT02489266
In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma treatment 1 withdrawn NCT02595866
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer treatment 1 completed NCT01042366
Dendritic Cells (DC) Vaccine for Metastatic Melanoma No drug interventions treatment 2 terminated NCT01280565
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit treatment 3 terminated NCT02626065
Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies other 4 unknown_status NCT00414765
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma treatment 4 completed NCT01701674
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts treatment Not Available active_not_recruiting NCT05361174
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer No drug interventions treatment 1 / 2 recruiting NCT01689974
Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma treatment 2 terminated NCT02740920
Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker treatment 2 terminated NCT02158520
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT02054520
Immunotherapy Study for Patients With Stage IV Melanoma treatment 2 terminated NCT03597282
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma treatment 1 terminated NCT04337931
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma treatment 2 terminated NCT00287131
Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients No drug interventions treatment 2 unknown_status NCT01236573
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes treatment 1 / 2 terminated NCT04217473
TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma treatment 1 active_not_recruiting NCT03326973
Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors No drug interventions Not Available Not Available completed NCT01029873
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma treatment 1 / 2 completed NCT01503827
Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma No drug interventions treatment Not Available unknown_status NCT04697576
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma treatment 1 recruiting NCT06236360
Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet No drug interventions supportive_care Not Available recruiting NCT03021460
Pembrolizumab and Ibrutinib in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery No drug interventions treatment 1 active_not_recruiting NCT00716560
Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin No drug interventions Not Available Not Available terminated NCT02791594
Imaging FDG Flare in Melanoma Not Available Not Available completed NCT03850691
Radiation and Combination Immunotherapy for Melanoma treatment 2 completed NCT05103891
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations other 1 unknown_status NCT01692691
Dacarbazine and Carmustine in Metastatic Melanoma treatment 2 terminated NCT02117362
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma treatment 1 completed NCT03698162
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases diagnostic Not Available terminated NCT00249262
Taxoprexin Treatment for Advanced Skin Melanoma No drug interventions treatment 2 completed NCT04955262
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab treatment 1 withdrawn NCT04645680
Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study No drug interventions supportive_care 2 active_not_recruiting NCT00121680
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma treatment 1 completed NCT03149029
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma treatment 2 active_not_recruiting NCT05611229
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden Not Available Not Available completed NCT01932489
The Jules Bordet Institute Molecular Profiling Program Feasibility Trial No drug interventions other Not Available completed NCT00679289
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma treatment 2 completed NCT05717140
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung treatment 1 not_yet_recruiting NCT05398640
Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma Not Available Not Available no_longer_available NCT05810740
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations other 1 completed NCT04752267
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases diagnostic 0 completed NCT01833767
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma treatment 2 withdrawn NCT00301067
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma treatment 1 / 2 completed NCT03013101
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma treatment 2 unknown_status NCT03514901
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. treatment 2 unknown_status NCT05727904
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. treatment 3 recruiting NCT01005472
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma treatment 1 completed NCT03724968
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression treatment 2 terminated NCT02858869
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases treatment 1 completed NCT01590069
Aerosolized Aldesleukin in Treating Patients With Lung Metastases treatment 1 active_not_recruiting NCT05304546
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma treatment 2 not_yet_recruiting NCT05954546
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings No drug interventions Not Available Not Available completed NCT04759846
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma treatment 1 withdrawn NCT04588246
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery treatment 3 recruiting NCT03865212
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma treatment 1 active_not_recruiting NCT01876212
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma treatment 2 completed NCT00668512
Intratumoral Injection Of Alpha-Gal Glycosphingolipids Not Available 1 completed NCT02177110
A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma No drug interventions Not Available Not Available completed NCT01273181
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes treatment 1 / 2 terminated NCT02379195
Peginterferon and TIL Therapy for Metastatic Melanoma treatment 1 / 2 completed NCT05607095
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma treatment 1 recruiting NCT03879395
Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study No drug interventions Not Available Not Available completed NCT01134250
Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients treatment 1 / 2 completed NCT00910650
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma treatment 2 completed NCT02306850
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma treatment 2 completed NCT02414750
Vemurafenib Plus Cobimetinib in Metastatic Melanoma other 2 terminated NCT05779423
Cryoablation+Ipilimumab+Nivolumab in Melanoma treatment 2 recruiting NCT01119508
Ipilimumab + Temozolomide in Metastatic Melanoma treatment 2 completed NCT01425008
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma treatment 1 completed NCT06066138
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing treatment 1 not_yet_recruiting NCT06469138
A Phase 1 Study to Investigate 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects treatment 1 completed NCT00597038
A Phase I/II Study of Dasatinib and Dacarbazine treatment 1 / 2 completed NCT02862743
Molecular Characterization of Advanced Stage Melanoma by Blood Sampling No drug interventions basic_science Not Available completed NCT02354690
Vemurafenib and TIL Therapy for Metastatic Melanoma treatment 1 / 2 completed NCT04899921
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets treatment 2 terminated NCT03674502
Safety of ADU-1604 in Adults With Metastatic Melanoma No drug interventions treatment 1 terminated NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV treatment 1 active_not_recruiting NCT02375984
A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas No drug interventions treatment 2 terminated NCT02126579
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists No drug interventions treatment 1 / 2 completed NCT04478279
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT02360579
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma treatment 2 active_not_recruiting NCT03875079
A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma treatment 1 completed NCT00203879
Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma treatment 2 completed NCT02713269
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord No drug interventions treatment 2 active_not_recruiting NCT03873818
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain treatment 2 active_not_recruiting NCT04140500
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors treatment 1 / 2 recruiting NCT03708328
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors treatment 1 completed NCT05704933
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases treatment 0 active_not_recruiting NCT01416831
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. treatment 2 active_not_recruiting NCT01644591
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases No drug interventions treatment 2 active_not_recruiting NCT04007744
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors treatment 1 recruiting NCT05655312
MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma No drug interventions treatment 1 / 2 recruiting NCT05786924
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers No drug interventions treatment 1 recruiting NCT06549439
eFLASH for Skin Lesions of Malignant Melanomas No drug interventions treatment Not Available not_yet_recruiting NCT01134614
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 active_not_recruiting NCT01319565
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... treatment 2 active_not_recruiting NCT02224781
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma treatment 3 active_not_recruiting NCT04129515
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis treatment 1 / 2 not_yet_recruiting NCT04511013
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases treatment 2 recruiting NCT04695977
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma treatment 2 / 3 completed NCT05155033
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma treatment 2 recruiting NCT05629546
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors treatment 1 not_yet_recruiting NCT01005745
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma treatment Not Available active_not_recruiting NCT03276832
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma treatment 0 active_not_recruiting NCT05470283
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma treatment 1 active_not_recruiting NCT01902173
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer treatment 1 / 2 active_not_recruiting NCT02581930
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma treatment 2 active_not_recruiting NCT03816332
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers treatment 1 active_not_recruiting NCT05026983
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases treatment 2 recruiting NCT06500455
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain No drug interventions treatment 3 not_yet_recruiting NCT03131908
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss treatment 1 / 2 active_not_recruiting NCT04272658
PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy No drug interventions Not Available Not Available recruiting NCT04903119
Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma treatment 1 recruiting NCT04955743
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma treatment 2 recruiting NCT05640193
A Study of LN-144 in People With Metastatic Melanoma to the Brain treatment 1 active_not_recruiting NCT06488365
In Vivo Liquid Biopsy of Melanoma (Cytophone) No drug interventions diagnostic Not Available not_yet_recruiting NCT05628883
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma treatment 1 recruiting NCT01659151
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma treatment 2 active_not_recruiting NCT02650986
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 treatment 1 / 2 active_not_recruiting NCT02700971
RATIO: Rational Approach To Immuno-Oncology No drug interventions basic_science Not Available completed NCT04557956
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment treatment 1 / 2 recruiting NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors treatment 1 / 2 recruiting NCT05764395
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors treatment 2 recruiting NCT05856565
Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1 No drug interventions Not Available Not Available recruiting NCT02298959
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer treatment 1 active_not_recruiting NCT02910700
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma treatment 2 active_not_recruiting NCT02631447
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study treatment 2 completed NCT03817125
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention treatment 1 completed NCT06060613
Safety and Efficacy of OBX-115 in Advanced Solid Tumors treatment 1 / 2 recruiting NCT04119024
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors treatment 1 recruiting NCT05034536
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma treatment 2 recruiting NCT05169957
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) treatment 1 active_not_recruiting NCT02419495
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies treatment 1 active_not_recruiting NCT03175432
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases treatment 2 active_not_recruiting NCT01989585
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma treatment 1 / 2 active_not_recruiting NCT04140526
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC treatment 1 / 2 recruiting NCT04940299
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma treatment 2 active_not_recruiting NCT02027935
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma treatment 2 completed NCT04693377
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial No drug interventions supportive_care Not Available recruiting NCT03122522
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy treatment 2 active_not_recruiting NCT01621490
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma basic_science 1 completed NCT05341349
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases treatment 1 recruiting NCT01955460
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma treatment 1 active_not_recruiting NCT04771520
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors treatment 2 recruiting NCT06369428
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients No drug interventions Not Available Not Available completed NCT03025256
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease treatment 1 active_not_recruiting NCT03625141
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases treatment 2 completed NCT03645928
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors treatment 2 recruiting NCT04625205
NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma No drug interventions treatment 1 recruiting NCT05913388
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma treatment 2 recruiting NCT02816021
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma treatment 2 active_not_recruiting NCT03590054
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies treatment 1 completed NCT04930783
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma treatment 1 recruiting NCT05388877
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma treatment 1 recruiting NCT05695898
XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy treatment 1 active_not_recruiting NCT01738139
Ipilimumab and Imatinib Mesylate in Advanced Cancer treatment 1 completed NCT01364051
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies treatment 1 active_not_recruiting NCT02678741
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. No drug interventions treatment 1 / 2 completed NCT06151847
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma treatment 2 recruiting NCT04698187
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma treatment 2 completed NCT03475134
TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL) treatment 1 active_not_recruiting NCT05578872
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). treatment 1 / 2 recruiting NCT06180460
CALM: Managing Distress in Malignant Brain Cancer No drug interventions supportive_care Not Available recruiting NCT04242329
Surgery of Melanoma Metastases After Systemic Therapy No drug interventions treatment 2 withdrawn NCT03888950
Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy No drug interventions other Not Available recruiting NCT03646617
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma treatment 2 recruiting NCT04109456
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma treatment 1 recruiting NCT04967196
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma treatment 1 active_not_recruiting NCT05155254
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) treatment 3 active_not_recruiting NCT03123783
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab treatment 1 / 2 completed NCT05393713
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study treatment 1 active_not_recruiting NCT04789668
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases treatment 1 / 2 completed NCT01856023
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma treatment 4 terminated NCT03229278
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma treatment 1 completed NCT02278887
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma treatment 3 active_not_recruiting NCT04793737
Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases No drug interventions treatment Not Available recruiting NCT02304458
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas treatment 1 / 2 completed NCT06075524
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types No drug interventions Not Available Not Available recruiting NCT02310451
Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes No drug interventions screening Not Available completed NCT03430297
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma treatment 3 active_not_recruiting NCT02748564
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma treatment 2 terminated NCT03679767
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) treatment 2 completed NCT03803397
Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma No drug interventions treatment 1 not_yet_recruiting NCT03898908
Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain treatment 2 active_not_recruiting NCT03864042
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors treatment 1 active_not_recruiting NCT04987996
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients treatment 2 withdrawn NCT05878977
Biomarkers in Immunotherapy of Melanoma No drug interventions treatment Not Available recruiting NCT05848219
Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib No drug interventions Not Available Not Available terminated NCT02141542
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma treatment 1 completed NCT01995344
TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment treatment 2 terminated NCT03474497
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade treatment 1 / 2 recruiting NCT03743298
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma No drug interventions treatment 1 recruiting NCT04960059
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts No drug interventions Not Available Not Available recruiting NCT02500576
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma treatment 2 completed NCT05750511
Multicenter Tissue Registry in Melanoma No drug interventions Not Available Not Available recruiting NCT03265080
A Study of ADXS-NEO Expressing Personalized Tumor Antigens treatment 1 terminated NCT03913923
Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma No drug interventions treatment 2 active_not_recruiting NCT05732805
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma treatment 3 recruiting NCT01993719
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma treatment 2 completed NCT05588453
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain treatment 1 / 2 recruiting NCT05641012
Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma No drug interventions Not Available Not Available not_yet_recruiting NCT04941365
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy No drug interventions diagnostic Not Available withdrawn NCT04911998
A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients No drug interventions Not Available Not Available recruiting NCT04698161
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Oncologic Diseases No drug interventions Not Available Not Available completed NCT04633902
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation treatment 2 recruiting NCT04158544
Immune Monitoring in Metastatic Melanoma No drug interventions Not Available Not Available unknown_status NCT04060407
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) treatment 1 / 2 withdrawn NCT04042506
SBRT as a Vaccination for Metastatic Melanoma treatment 2 withdrawn NCT04021420
Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma treatment 1 / 2 recruiting NCT03991741
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors treatment 1 recruiting NCT03925350
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation treatment 2 recruiting NCT03773744
MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma treatment 1 withdrawn NCT03728465
Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma treatment 2 terminated NCT03526185
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes treatment 0 terminated NCT03445533
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma treatment 3 terminated NCT03425461
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma treatment 1 terminated NCT03326258
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery treatment 1 / 2 withdrawn NCT03297463
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma treatment 1 / 2 withdrawn NCT03225365
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma No drug interventions other Not Available completed NCT03176485
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors No drug interventions prevention Not Available completed NCT03155217
Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old No drug interventions Not Available Not Available completed NCT03126461
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients treatment 2 withdrawn NCT03073473
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers No drug interventions Not Available Not Available terminated NCT03047928
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma treatment 1 / 2 recruiting NCT02857270
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer treatment 1 completed NCT02768207
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma screening 2 completed NCT02755233
Ipilimumab-induced Lung Toxicity: Observational Study No drug interventions Not Available Not Available completed NCT02644967
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma treatment 2 completed NCT02625337
Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients treatment 2 unknown_status NCT02608437
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients treatment 1 unknown_status NCT02521870
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma treatment 1 / 2 terminated NCT02424916
Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study No drug interventions treatment 1 / 2 completed NCT02392871
Radiotherapy & Combi in Metastatic Melanoma treatment 1 / 2 completed NCT02357732
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib treatment 1 withdrawn NCT02150369
Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms No drug interventions Not Available Not Available completed NCT02142335
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma treatment 2 unknown_status NCT02097732
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery treatment 2 terminated NCT02097225
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT02073123
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma treatment 1 / 2 completed NCT02062359
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma treatment 2 terminated NCT02009397
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients treatment 1 / 2 completed NCT02009384
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox treatment 2 terminated NCT01940809
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery treatment 1 terminated NCT01933061
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma treatment 2 withdrawn NCT01927419
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma treatment 2 completed NCT01920516
Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment Not Available Not Available unknown_status NCT01904123
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain treatment 1 completed NCT01878396
Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors No drug interventions Not Available Not Available unknown_status NCT01876641
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib treatment 1 terminated NCT01864538
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma treatment 2 terminated NCT01838200
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma treatment 1 terminated NCT01807182
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma treatment 2 completed NCT01743157
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma treatment 1 / 2 completed NCT01723813
Peptide Vaccinations Plus GM-CT-01 in Melanoma treatment 1 / 2 terminated NCT01702896
Interleukin-2 in Metastatic Melanoma treatment 2 terminated NCT01689870
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma treatment 1 / 2 withdrawn NCT01683188
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma other 4 terminated NCT01620749
Of 18F MEL050 Using PET/CT in Metastatic Melanoma No drug interventions diagnostic 0 unknown_status NCT01558349
Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques No drug interventions Not Available Not Available completed NCT01542255
Metronomic Therapy in Patients With Metastatic Melanoma treatment 2 terminated NCT01497808
RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA treatment 1 / 2 completed NCT01495988
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma treatment 2 terminated NCT01495572
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells treatment 2 terminated NCT01468818
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma treatment 2 terminated NCT01457131
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer treatment 1 terminated NCT01416844
Study of Immune Responses in Patients With Metastatic Melanoma No drug interventions treatment 2 withdrawn NCT01415167
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy No drug interventions Not Available Not Available completed NCT01369888
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma treatment 1 / 2 terminated NCT01369875
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma treatment 2 terminated NCT01340729
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma treatment 1 / 2 withdrawn NCT01335009
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma treatment 2 completed NCT01312506
Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls No drug interventions Not Available Not Available withdrawn NCT01258855
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT01218867
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer treatment 1 / 2 terminated NCT01216436
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma No drug interventions Not Available 1 terminated NCT01216696
Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 treatment 2 completed NCT01212276
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma No drug interventions treatment 1 terminated NCT01191034
Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma treatment 1 / 2 terminated NCT01160445
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer treatment 2 terminated NCT01118091
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... treatment 2 completed NCT01082887
A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg) No drug interventions treatment 1 / 2 terminated NCT01014351
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma treatment 2 completed NCT01011530
Dose Escalation Study of MLN4924 in Adults With Melanoma treatment 1 completed NCT00986661
A Study to Assess PV-10 Chemoablation of Cancer of the Liver treatment 1 active_not_recruiting NCT00984464
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma treatment 2 completed NCT00948480
Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells treatment 2 completed NCT00928031
Long-term Data Collection for Subjects in MDX-010 Studies No drug interventions Not Available Not Available completed NCT00925132
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat treatment 1 / 2 terminated NCT00881049
Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma treatment 2 completed NCT00804908
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma treatment 2 completed NCT00758797
A Novel Treatment for Metastatic Melanoma No drug interventions treatment 1 terminated NCT00734188
Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma No drug interventions treatment 1 completed NCT00733798
A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma treatment 1 / 2 terminated NCT00724841
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma treatment 1 / 2 terminated NCT00672542
Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells No drug interventions treatment 1 completed NCT00665470
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma treatment 2 completed NCT00631618
Clinical Trial of Sutent to Treat Metastatic Melanoma treatment 2 completed NCT00626860
The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma No drug interventions treatment 1 / 2 completed NCT00627419
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma treatment 2 terminated NCT00612222
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma treatment 2 terminated NCT00610311
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma treatment 2 terminated NCT00609011
Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma treatment 1 / 2 completed NCT00604136
Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy No drug interventions treatment 2 unknown_status NCT00591734
RAD001 Plus Bevacizumab in Metastatic Melanoma treatment 2 completed NCT00571116
Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy treatment 1 terminated NCT00553618
Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients treatment 2 active_not_recruiting NCT00527761
Taxotere/Temodar/Cisplatin Study in Melanoma Patients treatment 1 completed NCT00526617
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients treatment 1 completed NCT00520299
Study of ADI-PEG 20 in Patients With Advanced Melanoma No drug interventions treatment 1 / 2 completed NCT00402662
A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma treatment 2 terminated NCT00399113
Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma treatment 1 completed NCT00395070
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma treatment 3 completed NCT00383292
A Study of Tasisulam in Treating Participants With Malignant Melanoma treatment 2 completed NCT00348088
Melanoma Biomarker Study No drug interventions Not Available Not Available completed NCT00328861
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer treatment 2 completed NCT00314093
RFT-5-dgA in Patients With Metastatic Melanoma No drug interventions treatment 2 completed NCT00314106
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma treatment 2 completed NCT00308607
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma treatment 2 completed NCT00304460
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer treatment 1 completed NCT00279058
The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2 No drug interventions treatment 1 / 2 completed NCT00256282
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma treatment 2 completed NCT00244816
Taxoprexin® Treatment for Advanced Eye Melanoma No drug interventions treatment 2 completed NCT00226473
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma treatment 4 unknown_status NCT00223899
A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma No drug interventions treatment 1 completed NCT00153569
Multiepitope Peptide Vaccination in Melanoma treatment 2 unknown_status NCT00139360
Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma treatment 2 completed NCT00044356
Phase II Trial of Allovectin-7® for Metastatic Melanoma No drug interventions treatment 2 completed NCT03889782
High Dose IL-2 in Combination With Anti-PD-1 in Metastatic Melanoma and Renal Cell Carcinoma treatment 2 not_yet_recruiting NCT03427398
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma treatment 2 active_not_recruiting